Mast Therapeutics, Inc. (MSTX)

[BooDog]

•The Company also announced that patient enrollment is complete in a placebo-controlled Phase 2a study of AIR001 designed to measure its effect on cardiovascular hemodynamics in patients suffering from heart failure with preserved ejection fraction (HFpEF). Top-line results from this 30-patient, investigator-sponsored study are expected to be available this month. Preliminary results from an initial cohort of patients enrolled in a second investigator-sponsored Phase 2a study of AIR001 in HFpEF patients have been submitted for presentation at a scientific conference in May.


- Enrollment in largest-ever interventional Phase 3 trial in sickle cell disease has surpassed 90%; top-line data anticipated Q2 2016
- Enrollment in Phase 2a study of AIR001 in HFpEF is complete; top-line data expected this month
- Company ended 2015 with approximately $41M in cash, cash equivalents and investment securities

http://investorshub.advfn.com/boards/post_reply.aspx?message_id=119943415

Make sure news alerts are set for news.

You cannot find another company losing 90% of value in a 5 year period with CEO giving him self a 70% raise in the same time period

Wanna bet? Some of my best plays have been catching the bottom on some taken down even more. Navidia comes to mind. How about Actinium? Corbus?

I really hope he proves me wrong

From what I see with trials so far, on track and progressing nicely. Seems some just lack the patience for this sector. Certainly not the best sector to be in right now but then again, in a bear market where would you rather be? These start ups are not large cap divi paying stocks. Being here in the first place has its risk just as well as the large caps though imo. A matter of measure. And yes, time.

IMO, Mast has a better chance of moving from .40 to 3.5 / $4 quicker than many others on good results. Not to mention potential partnership.